Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Abstract

Clinical Trial RegistryEfficacy and Safety of GLP-1 first therapy compared with Insulin GLP-1 relay therapy in type 2 diabetes with inadequate glucose control: a randomized, open-label, multicenter parallelgroup study (UMIN000014140).